Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy.

Zammataro L;Lopez S;Bellone S;Pettinella F;Bonazzoli E;Perrone E;Zhao S;Menderes G;Altwerger G;Han C;Zeybek B;Bianchi A;Manzano A;Manara P;Cocco E;Buza N;Hui P;Wong S;Ravaggi A;Bignotti E;Romani C;Todeschini P;Zanotti L;Odicino F;Pecorelli S;Donzelli C;Ardighieri L;Angioli R;Raspagliesi F;Scambia G;Choi J;Dong W;Bilguvar K;Alexandrov LB;Silasi DA;Huang GS;Ratner E;Azodi M;Schwartz PE;Pirazzoli V;Stiegler AL;Boggon TJ;Lifton RP;Schlessinger J;Santin AD

2019-01-01